Acumen Pharmaceuticals (NASDAQ:ABOS) & Moleculin Biotech (NASDAQ:MBRX) Financial Survey

Moleculin Biotech (NASDAQ:MBRX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Moleculin Biotech and Acumen Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56 million	($17.98)	-0.13
Acumen Pharmaceuticals	N/A	N/A	-$121.33 million	($1.86)	-1.18

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Moleculin Biotech and Acumen Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1	0	2	0	2.33
Acumen Pharmaceuticals	1	0	3	0	2.50

Moleculin Biotech currently has a consensus price target of $22.00, suggesting a potential upside of 812.86%. Acumen Pharmaceuticals has a consensus price target of $6.67, suggesting a potential upside of 204.41%. Given Moleculin Biotech’s higher probable upside, equities analysts plainly believe Moleculin Biotech is more favorable than Acumen Pharmaceuticals.

Profitability

This table compares Moleculin Biotech and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Volatility and Risk

Moleculin Biotech has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Summary

Moleculin Biotech beats Acumen Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.